Point72 Asset Management’s ImmunityBio IBRX Stock Holding History

Point72 Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.23M	Buy	+160,100	New	+$1.1M	﹤0.01%	2620

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management's IBRX Position: Q4 2023 in Review

Point72 Asset Management sold out of ImmunityBio (IBRX) in Q4 2023, closing a stake of 15,500 shares — an estimated $26.2K sold.

Point72 Asset Management first reported a position in IBRX in Q1 2023 and held it in 2 quarters. The position peaked at $194K in Q1 2023. 147 funds tracked by Wall St. Rank hold IBRX as of Q4 2023.

Point72 Asset Management reported no remaining ImmunityBio position as of Q4 2023 after selling out during the quarter.
Point72 Asset Management sold 15,500 ImmunityBio shares in Q4 2023, an estimated $26.2K.
Point72 Asset Management first reported a position in ImmunityBio in Q1 2023 and held it in 2 quarters.
Point72 Asset Management's ImmunityBio position peaked at $194K in Q1 2023.
147 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.